Acquisition Includes a Therapeutic in Phase 3 Clinical Trials for the Treatment of Advanced Melanoma and Head and Neck Cancer.

Amgen, today announced the completion of the acquisition of BioVex Group, Inc., a privately held, biotechnology company based in Woburn, Mass., with additional operations in Abingdon, UK. The transaction provides Amgen with BioVex’s lead product candidate, OncoVEXGM-CSF, a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer. The acquisition was initially announced on Jan. 24 and includes a $ 425 Million upfront plus up to $ 575 Million additional milestone payments.